Tokyo Tape
Sign in
← ASKA Pharmaceutical Holdings

Annual report

4886.TEDINET S100R645
Period2022-04-01 → 2023-03-31
Filed2023-06-27
StandardJapan GAAP
ConsolidatedYes
Data checks22 of 22 passed
Key figures · 72
MetricValuePeriodScopeSource row
Revenue¥60.5bn2022-04-01 → 2023-03-31Cons.Net sales
Revenue¥56.6bn2021-04-01 → 2022-03-31Cons.Net sales
Operating income¥5.1bn2022-04-01 → 2023-03-31Cons.Operating income
Operating income¥4.8bn2021-04-01 → 2022-03-31Cons.Operating income
Ordinary income¥5.2bn2022-04-01 → 2023-03-31Cons.Ordinary income
Ordinary income¥4.9bn2021-04-01 → 2022-03-31Cons.Ordinary income
Profit before tax¥5.4bn2022-04-01 → 2023-03-31Cons.Income before income taxes
Profit before tax¥6.2bn2021-04-01 → 2022-03-31Cons.Income before income taxes
Net income (owners)¥4.2bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.3bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent
Net income¥4.2bn2022-04-01 → 2023-03-31Cons.Profit loss
Net income¥4.3bn2021-04-01 → 2022-03-31Cons.Profit loss
Total assets¥87.1bnat 2023-03-31Cons.Assets
Total assets¥83.3bnat 2022-03-31Cons.Assets
Total liabilities¥32.6bnat 2023-03-31Cons.Liabilities
Total liabilities¥34.4bnat 2022-03-31Cons.Liabilities
Net assets / equity¥54.5bnat 2023-03-31Cons.Net assets
Net assets / equity¥48.9bnat 2022-03-31Cons.Net assets
Net assets / equity¥44.5bnat 2021-03-31dCons.Net assets
Cash and deposits¥14.5bnat 2023-03-31Cons.Cash and deposits
Cash and deposits¥12.1bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥17.5bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥17.1bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥10.5bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥3.4bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities
Operating cash flow¥2.8bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities
Investing cash flow−¥1.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investment activities
Investing cash flow¥6.7bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investment activities
Financing cash flow−¥1.8bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥3.0bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities
EPS (basic)¥150.082022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥151.222021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
Net assets per share¥1,928.14at 2023-03-31Cons.Net assets per share (5-year summary)
Net assets per share¥1,734.8at 2022-03-31Cons.Net assets per share (5-year summary)
Equity ratio62.6%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio58.7%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
ROE8.2%2022-04-01 → 2023-03-31Cons.Rate of return on equity (5-year summary)
ROE8.8%2021-04-01 → 2022-03-31Cons.Rate of return on equity (5-year summary)
Employees747at 2023-03-31Cons.Number of employees
Employees777at 2022-03-31Cons.Number of employees
Revenue¥1.7bn2022-04-01 → 2023-03-31StandaloneOperating revenue1
Revenue¥1.4bn2021-04-01 → 2022-03-31StandaloneOperating revenue1
Operating income¥658m2022-04-01 → 2023-03-31StandaloneOperating income
Operating income¥717m2021-04-01 → 2022-03-31StandaloneOperating income
Ordinary income¥603m2022-04-01 → 2023-03-31StandaloneOrdinary income
Ordinary income¥717m2021-04-01 → 2022-03-31StandaloneOrdinary income
Profit before tax¥603m2022-04-01 → 2023-03-31StandaloneIncome before income taxes
Profit before tax¥717m2021-04-01 → 2022-03-31StandaloneIncome before income taxes
Net income¥591m2022-04-01 → 2023-03-31StandaloneProfit loss
Net income¥682m2021-04-01 → 2022-03-31StandaloneProfit loss
Total assets¥41.6bnat 2023-03-31StandaloneAssets
Total assets¥41.3bnat 2022-03-31StandaloneAssets
Total liabilities¥630mat 2023-03-31StandaloneLiabilities
Total liabilities¥606mat 2022-03-31StandaloneLiabilities
Net assets / equity¥40.9bnat 2023-03-31StandaloneNet assets
Net assets / equity¥40.7bnat 2022-03-31StandaloneNet assets
Cash and deposits¥1.1bnat 2023-03-31StandaloneCash and deposits
Cash and deposits¥820mat 2022-03-31StandaloneCash and deposits
EPS (basic)¥20.952022-04-01 → 2023-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥23.792021-04-01 → 2022-03-31StandaloneBasic earnings loss per share (5-year summary)
Dividend per share¥162022-04-01 → 2023-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥152021-04-01 → 2022-03-31StandaloneDividend paid per share (5-year summary)
Net assets per share¥1,447.55at 2023-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥1,443.94at 2022-03-31StandaloneNet assets per share (5-year summary)
Equity ratio98.5%at 2023-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio98.5%at 2022-03-31StandaloneEquity to asset ratio (5-year summary)
ROE1.5%2022-04-01 → 2023-03-31StandaloneRate of return on equity (5-year summary)
ROE1.7%2021-04-01 → 2022-03-31StandaloneRate of return on equity (5-year summary)
Shares issued30,563,199at 2023-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued30,563,199at 2022-03-31StandaloneTotal number of issued shares (5-year summary)
Employees79at 2023-03-31StandaloneNumber of employees
Employees74at 2022-03-31StandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 55
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsemployeesat 2023-03-3114 pure
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2023-03-31¥298m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2023-03-31¥220m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2023-03-31¥77m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment assetsat 2023-03-31¥42m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2023-03-31−¥6m
Reconciling Itemsreconcilingdepreciation2022-04-01 → 2023-03-31¥481m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2023-03-31−¥77m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2023-03-31−¥77m
Reconciling Itemsreconcilingsegment assetsat 2023-03-31¥43.9bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2023-03-31−¥1.1bn
Animal Health Businessreportable segmentdepreciation2022-04-01 → 2023-03-31¥4m
Animal Health Businessreportable segmentemployeesat 2023-03-3136 pure
Animal Health Businessreportable segmentrevenue2022-04-01 → 2023-03-31¥6.7bn
Animal Health Businessreportable segmentrevenue external2022-04-01 → 2023-03-31¥6.7bn
Animal Health Businessreportable segmentsegment assetsat 2023-03-31¥3.0bn
Animal Health Businessreportable segmentsegment profit2022-04-01 → 2023-03-31¥409m
Pharmaceutical Businessreportable segmentdepreciation2022-04-01 → 2023-03-31¥2.5bn
Pharmaceutical Businessreportable segmentemployeesat 2023-03-31610 pure
Pharmaceutical Businessreportable segmentrevenue2022-04-01 → 2023-03-31¥53.6bn
Pharmaceutical Businessreportable segmentrevenue external2022-04-01 → 2023-03-31¥53.6bn
Pharmaceutical Businessreportable segmentsegment assetsat 2023-03-31¥40.1bn
Pharmaceutical Businessreportable segmentsegment profit2022-04-01 → 2023-03-31¥5.8bn
Total Of Reportable Segments And Otherssegment totaldepreciation2022-04-01 → 2023-03-31¥2.5bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2023-03-31¥60.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2023-03-31¥60.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2023-03-31¥77m
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2023-03-31¥43.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2023-03-31¥6.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2022-03-31¥259m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2022-03-31¥185m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2022-03-31¥73m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment assetsat 2022-03-31¥90m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2022-03-31−¥16m
Reconciling Itemsreconcilingdepreciation2021-04-01 → 2022-03-31¥136m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2022-03-31−¥73m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2022-03-31−¥73m
Reconciling Itemsreconcilingsegment assetsat 2022-03-31¥37.3bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2022-03-31−¥653m
Animal Health Businessreportable segmentdepreciation2021-04-01 → 2022-03-31¥4m
Animal Health Businessreportable segmentrevenue2021-04-01 → 2022-03-31¥5.6bn
Animal Health Businessreportable segmentrevenue external2021-04-01 → 2022-03-31¥5.6bn
Animal Health Businessreportable segmentsegment assetsat 2022-03-31¥3.0bn
Animal Health Businessreportable segmentsegment profit2021-04-01 → 2022-03-31¥376m
Pharmaceutical Businessreportable segmentdepreciation2021-04-01 → 2022-03-31¥2.5bn
Pharmaceutical Businessreportable segmentrevenue2021-04-01 → 2022-03-31¥50.8bn
Pharmaceutical Businessreportable segmentrevenue external2021-04-01 → 2022-03-31¥50.8bn
Pharmaceutical Businessreportable segmentsegment assetsat 2022-03-31¥42.9bn
Pharmaceutical Businessreportable segmentsegment profit2021-04-01 → 2022-03-31¥5.1bn
Total Of Reportable Segments And Otherssegment totaldepreciation2021-04-01 → 2022-03-31¥2.6bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2022-03-31¥56.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2022-03-31¥56.6bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2022-03-31¥73m
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2022-03-31¥46.0bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2022-03-31¥5.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,440
ItemContextValueUnit
Cash and depositsPrior1YearInstant_NonConsolidatedMember820000000JPY
Cash and depositsCurrentYearInstant_NonConsolidatedMember1120000000JPY
Other caPrior1YearInstant_NonConsolidatedMember134000000JPY
Other caCurrentYearInstant_NonConsolidatedMember79000000JPY
Current assetsPrior1YearInstant_NonConsolidatedMember954000000JPY
Current assetsCurrentYearInstant_NonConsolidatedMember1200000000JPY
Stocks of subsidiaries and affiliatesPrior1YearInstant_NonConsolidatedMember40319000000JPY
Stocks of subsidiaries and affiliatesCurrentYearInstant_NonConsolidatedMember40319000000JPY
Deferred tax assetsPrior1YearInstant_NonConsolidatedMember27000000JPY
Deferred tax assetsCurrentYearInstant_NonConsolidatedMember54000000JPY
Investments and other assetsPrior1YearInstant_NonConsolidatedMember40347000000JPY
Investments and other assetsCurrentYearInstant_NonConsolidatedMember40374000000JPY
Noncurrent assetsPrior1YearInstant_NonConsolidatedMember40347000000JPY
Noncurrent assetsCurrentYearInstant_NonConsolidatedMember40374000000JPY
AssetsPrior1YearInstant_NonConsolidatedMember41301000000JPY
AssetsCurrentYearInstant_NonConsolidatedMember41575000000JPY
Short term loans payablePrior1YearInstant_NonConsolidatedMember300000000JPY
Short term loans payableCurrentYearInstant_NonConsolidatedMember300000000JPY
Current portion of long term loans payablePrior1YearInstant_NonConsolidatedMember48000000JPY
Current portion of long term loans payableCurrentYearInstant_NonConsolidatedMember48000000JPY
Accounts payable otherPrior1YearInstant_NonConsolidatedMember33000000JPY
Accounts payable otherCurrentYearInstant_NonConsolidatedMember81000000JPY
Income taxes payablePrior1YearInstant_NonConsolidatedMember39000000JPY
Income taxes payableCurrentYearInstant_NonConsolidatedMember29000000JPY
Provision for bonusesPrior1YearInstant_NonConsolidatedMember60000000JPY
Provision for bonusesCurrentYearInstant_NonConsolidatedMember116000000JPY
Other clPrior1YearInstant_NonConsolidatedMember75000000JPY
Other clCurrentYearInstant_NonConsolidatedMember55000000JPY
Current liabilitiesPrior1YearInstant_NonConsolidatedMember557000000JPY
Current liabilitiesCurrentYearInstant_NonConsolidatedMember630000000JPY
Long term loans payablePrior1YearInstant_NonConsolidatedMember48000000JPY
Long term loans payableCurrentYearInstant_NonConsolidatedMember－JPY
Noncurrent liabilitiesPrior1YearInstant_NonConsolidatedMember48000000JPY
Noncurrent liabilitiesCurrentYearInstant_NonConsolidatedMember－JPY
LiabilitiesPrior1YearInstant_NonConsolidatedMember606000000JPY
LiabilitiesCurrentYearInstant_NonConsolidatedMember630000000JPY
Capital stockPrior1YearInstant_NonConsolidatedMember1197000000JPY
Capital stockCurrentYearInstant_NonConsolidatedMember1197000000JPY
Legal capital surplusPrior1YearInstant_NonConsolidatedMember844000000JPY
Legal capital surplusCurrentYearInstant_NonConsolidatedMember844000000JPY
Other capital surplusPrior1YearInstant_NonConsolidatedMember41239000000JPY
Other capital surplusCurrentYearInstant_NonConsolidatedMember41220000000JPY
Capital surplusPrior1YearInstant_NonConsolidatedMember42084000000JPY
Capital surplusCurrentYearInstant_NonConsolidatedMember42065000000JPY
Other retained earningsPrior1YearInstant_NonConsolidatedMember747000000JPY
Other retained earningsCurrentYearInstant_NonConsolidatedMember886000000JPY
Retained earnings brought forwardPrior1YearInstant_NonConsolidatedMember747000000JPY
Retained earnings brought forwardCurrentYearInstant_NonConsolidatedMember886000000JPY
Retained earningsPrior1YearInstant_NonConsolidatedMember747000000JPY
Retained earningsCurrentYearInstant_NonConsolidatedMember886000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 22 of 22 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identitynon_consolidated 2022-03-31pass
balance sheet identitynon_consolidated 2023-03-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsnon_consolidated 2022-03-31pass
statement vs summary · net assetsnon_consolidated 2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2022-03-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2022-03-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2023-03-31pass
statement vs summary · revenueconsolidated 2021-04-01/2022-03-31pass
statement vs summary · revenueconsolidated 2022-04-01/2023-03-31pass
statement vs summary · revenuenon_consolidated 2021-04-01/2022-03-31pass
statement vs summary · revenuenon_consolidated 2022-04-01/2023-03-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsnon_consolidated 2022-03-31pass
statement vs summary · total assetsnon_consolidated 2023-03-31pass